LEVOPHED

This brand name is authorized in Canada, Hong Kong, New Zealand, Singapore, United States

Active ingredients

The drug LEVOPHED contains one active pharmaceutical ingredient (API):

1 Noradrenaline UNII IFY5PE3ZRW - NOREPINEPHRINE BITARTRATE

Noradrenaline provides a strong stimulation of alpha receptors in blood vessels at which these are counter-extracted. Noradrenaline also has an effect on beta-1 receptors in the heart leading to a positive inotropic and initially positive chronotropic effect. The increase in blood pressure may cause a reflex reduction in heart rate. Read about Noradrenaline

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C01CA03	Norepinephrine	C Cardiovascular system → C01 Cardiac therapy → C01C Cardiac stimulants excl. cardiac glycosides → C01CA Adrenergic and dopaminergic agents
Discover more medicines within C01CA03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02241981
Country: HK	Department of Health Drug Office	Identifier(s): 43632, 65386
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 16221
Country: SG	Health Sciences Authority	Identifier(s): 05754P, 15297P
Country: US	FDA, National Drug Code	Identifier(s): 0409-3375, 51662-1315